CIK 0001664710
- Non-accelerated filer
- Smaller reporting company
Keros Therapeutics, Inc.
Sign in to watch- Ticker
- KROS
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- Operating
- EIN
- 811173868
- Phone
- +1 617-314-6297
- Business address
- 1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $5,619
- in 1 filing, $6K under 10b5-1 plans
Net −$5,619. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2020-04-13 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Purchase | +94,546 | $16.00 | $1.5M | 1,109,802 |
| 2020-04-13 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Purchase | +105,000 | $16.00 | $1.7M | 1,213,926 |
| 2020-04-13 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Purchase | +43,750 | $16.00 | $700K | 149,262 |
| 2020-04-13 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Conversion · Series A Preferred Stock | −1,363,542 | 0 | ||
| 2020-04-13 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Conversion · Series A Preferred Stock | −663,825 | 0 | ||
| 2020-04-13 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Conversion · Series A Preferred Stock | −737,226 | 0 | ||
| 2020-04-13 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Conversion · Series B-1 Preferred Stock | −169,307 | 0 | ||
| 2020-04-13 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Conversion · Series B-1 Preferred Stock | −82,425 | 0 | ||
| 2020-04-13 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Conversion · Series B-1 Preferred Stock | −91,538 | 0 | ||
| 2020-04-13 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Conversion · Series B-1 Preferred Stock | −68,654 | 0 | ||
| 2020-04-13 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Conversion · Series C Preferred Stock | −163,612 | 0 | ||
| 2020-04-13 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Conversion · Series C Preferred Stock | −88,460 | 0 | ||
| 2020-04-13 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Conversion · Series C Preferred Stock | −79,653 | 0 | ||
| 2020-04-13 | Pontifax Management 4 G.P. (2015) Ltd. 10% owner | Conversion · Series C Preferred Stock | −36,858 | 0 | ||
| 2020-04-13 | ORBIMED ADVISORS LLC Director | Conversion | +744,612 | 744,612 | ||
| 2020-04-13 | ORBIMED ADVISORS LLC Director | Conversion | +148,922 | 148,922 | ||
| 2020-04-13 | ORBIMED ADVISORS LLC Director | Purchase | +375,200 | $16.00 | $6.0M | 1,119,812 |
| 2020-04-13 | ORBIMED ADVISORS LLC Director | Conversion · Series C Preferred Stock | −744,612 | 0 | ||
| 2020-04-13 | ORBIMED ADVISORS LLC Director | Conversion · Series C Preferred Stock | −148,922 | 0 | ||
| 2020-04-13 | Nussbaum Ran Director | Conversion | +1,363,542 | 1,734,395 |
Page 31 of 36 · 707 trades